October 18, 2018, via ACOG

Attend the Education in Women's Genomics Counseling course on Friday, December 7, 2018 in Washington, D.C.
 
This grant-based course is designed to enhance physicians' knowledge and application of genomic technologies in the fields of reproductive healthcare. 

ABOUT THIS COURSE

Learn how to solicit a family history to identify appropriate genetic screening, how to counsel a preconception and prenatal patient on new carrier screening and aneuploidy screening options, and the implications of positive and negative test results. You will be able to discuss the pros and cons of new genetic test options for patients seeking prenatal diagnostic testing and recognize and counsel patients about hereditary cancer syndromes relevant to women's health and develop an evidence-based testing strategy.

EARN UP TO 18 CME CREDITS

1. Attend the didactic lecture ($99 holding fee refunded upon attendance)
2. Complete eight online modules by April 30, 2019 (information to be provided) 
3. Attend a three-hour lecture in person at the 2019 ACOG Annual Clinical and Scientific Meeting on May 5 or virtually up to seven days after the course
4. Successfully complete posttest 

October 17, 2018   

Save the date for AAPA 2019 in Denver Colorado, May 18-22, 2019! 

Plans for APAOG members include an awards reception and dinner. Meet fellow APAOG members as you come together  to learn about all things PA at AAPA 2019! 

More information to come. Stay tuned! 

MedPage Today, October 17, 2018  

Most examined patients with HIV who survived more than 2 years after allogeneic hematopoietic stem cell transplant (allo-HSCT) had undetectable HIV DNA and undetectable replication-competent virus, a small observational study found. 

Read more.

Medgadget, October 17, 2018  

GE Healthcare is unveiling its brand new Invenia Automated Breast Ultrasound (ABUS) 2.0 in the U.S. It is the only U.S. Food and Drug Administration approved "ultrasound supplemental breast screening technology," which allows for spotting of cancerous lesions within dense breast tissue, according to GE. 

Read more.

October 12, 2018, The Daily Telegraph  

Women could be spared the heartbreak of miscarriage thanks to artificial intelligence that can help to spot which pregnancies will fail. The breakthrough works with IVF treatment, using a super-computer to pick out "good" embryos — or "bad" ones, which could prevent a woman from giving birth or cause her to miscarry.

Read more.

October 10, 2018, News Medical 

The proportion of breast cancer patients who are eligible for breast conservation therapy, yet opt for mastectomy, is increasing, for reasons that include the desire to eliminate future screening and/or biopsy of the remaining breast tissue. A new study led by researchers at the Icahn School of Medicine at Mount Sinai has determined that having a mastectomy does not completely eliminate the need for further breast imaging studies.  

Read more.

October 9, 2018, HealthDay News  

More than 14 million additional 11- to 12-year-olds need to be vaccinated to reach the American Cancer Society goal of 80 percent of adolescents being up to date (UTD) with the human papillomavirus vaccination (HPVV) by their 13th birthday by 2026, according to a study published online in Cancer. 

Read more.

AAPA  

PA Week is here, and we have everything you need to celebrate. Print banners, promote the profession, participate in our Instagram photo contest, watch our PA Week Video contest submissions and vote for your favorite, and — most importantly, share your PA pride! 

Read more.

October 5, 2018, Infections Disease Advisor via Monthly Prescribing Reference  

The use of a moderate to low susceptibility antibiotic to treat a urinary tract infection (UTI) may result in a 1.74-fold increase in the odds of an emergency department readmission within 30 days for another UTI, according to a study presented at the IDWeek in San Francisco, Oct. 3-7.  

Read more.

October 5, 2018, Healio  

Most women who received an injection of brexanolone — a positive allosteric modulator of -aminobutyric-acid type A receptors — for postpartum depression had significant and clinically meaningful reductions of the condition at 60 hours vs. placebo, according to findings recently published in The Lancet. 

Read more.